July 25th Options Now Available For Biogen (BIIB)

Investors in Biogen (BIIB) can consider options strategies to enhance yield, according to Stock Options Channel. Selling the $129 put offers a potential 2.71% return (19.81% annualized) if it expires worthless, with a 58% probability based on current analytics; conversely, a covered call strategy selling the $132 call provides a possible 4.24% return if the stock is called away, or a 3.44% boost (25.09% annualized) if it expires worthless, with a 49% probability. The implied volatility for both options is approximately 35%, while the trailing twelve-month volatility is 29%.

Analysis

For Biogen Inc. (BIIB), currently trading at $130.95 per share, the article details two options strategies for yield enhancement or discounted share acquisition. Selling the $129.00 strike put contract, approximately 1% out-of-the-money (OTM), generates a $3.50 premium, leading to an effective cost basis of $125.50 if assigned; current analytics indicate a 58% probability of this put expiring worthless, which would result in a 2.71% return on cash, equivalent to a 19.81% annualized YieldBoost. Alternatively, for existing BIIB shareholders, selling a $132.00 strike covered call (also ~1% OTM) for a $4.50 premium presents a potential 4.24% total return if the shares are called away by the July 25th expiration. Should this call expire worthless, an event with a 49% probability, it offers a 3.44% additional return, or a 25.09% annualized YieldBoost. The implied volatility for both option contracts stands at approximately 35%, notably higher than Biogen's trailing twelve-month actual volatility of 29%, suggesting premiums may be elevated relative to recent realized price movements and reflecting market anticipation of future price variability.

Key Decisions for Investors

• Investors interested in acquiring Biogen shares below the current market price of $130.95 could consider selling the $129 put, which offers an effective entry point of $125.50 if assigned or a potential 19.81% annualized return on cash if the option expires worthless.
• Current Biogen shareholders seeking to generate income could evaluate selling the $132 covered call; this strategy offers a potential 4.24% return if the stock is called away by the July 25th expiration or a 3.44% premium enhancement (25.09% annualized) if the option expires unexercised.
• The observed implied volatility of approximately 35%, exceeding the 29% trailing twelve-month historical volatility, suggests that option sellers are currently compensated with higher premiums, but this also implies an expectation of greater stock price movement; investors should weigh this increased premium against the potential for higher volatility when considering these strategies.